Ignite Creation Date:
2025-12-25 @ 12:45 AM
Ignite Modification Date:
2026-01-22 @ 3:23 PM
Study NCT ID:
NCT02184767
Status:
COMPLETED
Last Update Posted:
2021-11-12
First Post:
2014-07-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-07
Start Date Type:
None
Primary Completion Date:
2015-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-05
Completion Date Type:
ACTUAL
First Submit Date:
2014-07-03
First Submit QC Date:
None
Study First Post Date:
2014-07-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-11-05
Last Update Post Date:
2021-11-12
Last Update Post Date Type:
ACTUAL